Organisational Aspects of Pediatric Parenteral Nutrition

Parenteral nutrition (PN) is a lifesaving therapy for children who cannot meet their nutritional needs enterally. The European societiesESPGHAN (European Society for Paediatric Gastroenterology, Hepatology and Nutrition), ESPEN (European Society for Clinical Nutrition and Metabolism) and ESPR (European Society for Paediatric Research)have produced joint guidelines that not only address clinical prescriptions but also the organisational framework required to deliver safe, highquality PN.

1. Multidisciplinary Team (MDT) Structure

All three societies stress that a dedicated PN team is essential. The core composition includes:

• Pediatric gastroenterologist / metabolic specialist Champions the clinical indication and monitors diseasespecific needs.
• Clinical pharmacist with expertise in PN Responsible for compounding, stability checks and drugnutrient interactions.
• Registered dietitian/nutrition support specialist Calculates macro and micronutrient requirements, adjusts prescriptions and follows growth parameters.
• Nurse specialist in nutrition support Oversees catheter care, administers solutions and educates families.
• Laboratory scientist Provides timely biochemical monitoring (electrolytes, liver function, triglycerides, trace elements).

Optional members are a pediatric surgeon (for catheter placement), a psychologist (for chronic cases) and a healtheconomics officer (for costeffectiveness monitoring).

2. Centralised vs. Decentralised Services

Centralised units (often located in tertiary hospitals) are recommended for patients requiring longterm or complex PN (e.g., shortbowel syndrome, severe malabsorption). Advantages include:

• Standardised compounding facilities (ISO7 clean rooms, aseptic technique).
• Uniform qualitycontrol protocols and batchrelease documentation.
• Greater experience with rare complications such as catheterrelated bloodstream infection (CRBSI) and intestinal failureassociated liver disease (IFALD).

Decentralised services (community hospitals, homecare providers) may manage stable patients on standardised, commercially available multichamber bags after discharge. The ESPGHAN/ESPEN/ESPR recommendations require a clear handover process, documented protocols and regular audits to ensure safety.

3. Standardised Prescription and Documentation

All societies endorse the use of a structured prescription template that includes:

• Patient identifiers, weight, height, and age.
• Indication for PN and anticipated duration.
• Exact macronutrient targets (g/kg/day of protein, kcal/kg/day, glucose infusion rate, lipid dosage).
• Micronutrient supplementation (vitamins, trace elements) adjusted for age and specific disease.
• Fluid volume, electrolyte composition, and osmolarity.
• Catheter type, lumens and insertion site.
• Prescribers signature, date, and review interval.

Electronic healthrecord integration is strongly recommended to avoid transcription errors and to enable automatic alerts for outofrange values.

4. Compounding Facilities and Quality Assurance

Guidelines require a dedicated aseptic pharmacy unit that complies with:

• EU GMP (Good Manufacturing Practice) for sterile medicinal products.
• ISO 57 cleanroom classification with validated laminarflow hoods.
• Regular microbiological environmental monitoring (settle plates, contact plates).
• Batch release testing for sterility, pyrogenicity, and correct osmolality.
• Traceability: each bag must carry a unique barcode linking it to the prescription, compounding date, and staff involved.

5. Delivery Models: InHospital, Home, and Hybrid

Inhospital PN is indicated for unstable patients, those requiring frequent adjustments, or when central venous access is new.

Home PN (HPN) is supported for children with chronic intestinal failure who meet the following criteria (per ESPEN/ESPR):

• Stable metabolic status for at least 2 weeks.
• Reliable caregiver training and psychosocial support.
• Access to a 24hour emergency line and rapidresponse team.

Hybrid models involve shortterm outpatient PN with daily or weekly pharmacy visits for bag preparation and line care, useful for patients transitioning from hospital to home.

6. Monitoring and Followup Protocols

Effective organisational frameworks incorporate a schedule of clinical and laboratory assessments:

7. Education, Training and Competency

All three societies insist on formal training programmes for each MDT member. Core elements include:

• Principles of aseptic technique and sterile compounding.
• Recognition and management of CRBSI, IFALD, metabolic complications.
• Family education modules covering catheter handling, bag storage, and emergency procedures.
• Annual competency assessments and documentation of continuingeducation credits.

8. Safety and Risk Management

Key organisational safeguards:

• Standard operating procedures (SOPs) for every stepfrom prescription to disposal.
• Incident reporting system linked to a rootcause analysis database.
• Regular internal audits (minimum quarterly) covering sterility, dosing accuracy, and compliance with prescription templates.
• Implementation of a doublecheck system: two qualified professionals must independently verify each PN bag before release.

9. Cost Considerations and Resource Allocation

While patient safety remains paramount, ESPEN emphasises costeffectiveness. Strategies include:

• Using commercially produced multichamber bags for stable patients to reduce compounding time.
• Batch preparation of identical prescriptions to minimise waste.
• Negotiating contracts with suppliers for trace elements and lipid emulsions.
• Tracking outcomes (e.g., length of stay, infection rates) to justify investment in centralised services.

10. Research, Audit and Continuous Improvement

ESPR advocates that every PN service participates in prospective data collection, preferably within national or European registries (e.g., ESPEN NutritionDay, ESPGHAN/ESPR Paediatric Intestinal Failure Registry). Audits should focus on:

• Compliance with guidelinebased prescriptions.
• Incidence of CRBSI, metabolic derangements, and IFALD.
• Patientreported outcomes such as quality of life and caregiver burden.

Findings must be reviewed by the MDT and fed back into SOP revisions, education modules, and policy updates.

Conclusion

The ESPGHAN, ESPEN and ESPR guidelines converge on the principle that highquality pediatric parenteral nutrition is achieved through a wellstructured, multidisciplinary organisation. Central to this is a dedicated PN team, standardised prescription and compounding processes, rigorous monitoring, and a culture of safety and continuous learning. Implementing these organisational pillars enables clinicians to meet the complex nutritional needs of children while minimising complications and preserving resources.

For the full guideline texts and supplementary tools, visit:

• ESPGHAN
• ESPEN
• ESPR